Dr. Elizabeth Verna is the Frank Cardile Associate Professor of Medicine and the Director of Hepatology at Columbia University Irving Medical Center, where she practices as transplant hepatologist. Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center. She has been involved in the AASLD since the beginning of her career and is now particularly honored to Chair the AASLD Practice Guidelines Committee.

Following gastroenterology and transplant hepatology fellowships at Mount Sinai Hospital, Stephanie joined the faculty at Weill-Cornell Medical Center/New York Presbyterian Hospital in July 2023 to pursue an academic career focused on clinical/translational research in hepatology.<br><br>She is intrigued by genomics and is using biobank data to evaluate the effects of genetic variants on liver disease risk in racially and ethnically diverse populations.

Neehar Parikh MD, MS, FAASLD, is an Associate Professor of Transplant Hepatology and Medical Director of the Liver Tumor Program and Director of Clinical Hepatology at the University of Michigan. He completed his residency, chief residency and gastroenterology and transplant hepatology training at Northwestern University in Chicago. He also received a Masters Degree in Health Services and Outcome Research from Northwestern University in 2013. His research interests include management of complications of cirrhosis and the early detection and treatment of hepatocellular carcinoma.

Harrys A. Torres, MD, FACP, FIDSA, FAASLD is a Professor of Medicine in the Department of Infectious Diseases, Infection Control, and Employee Health and an Adjunct Professor in the Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and infectious disease, with additional accreditations in HIV/AIDS and Tropical Medicine and Hygiene.

Dr. Hayashi is the Associate Director of DILI within the Division of Hepatology and Nutrition, FDA. He received his Bachelor of Arts in microbiology at UCLA and MD at University of California (UC), San Diego. After completing residency and gastroenterology fellowship at UC Davis in Sacramento, California, he completed a clinical research fellowship in the Liver Diseases Section, NIDDK, NIH. He then completed a transplant fellowship at the University of Colorado, Denver. He completed a Master of Public Health at Saint Louis University (SLU), St.

Dr. Dina Halegoua-De Marzio is a full time transplant hepatologist and is currently a Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University. She completed her residency in internal medicine and fellowships in gastroenterology and transplant hepatology at Thomas Jefferson University Hospital (TJUH). She developed the first adult Fatty Liver Center in the Delaware Valley and currently serves as its director. She also serves as the Director of GI Research at TJUH and Associate Chief for the Division of Gastroenterology and Hepatology.

I am an Associate Professor at Beth Israel Deaconess Medical Center/Harvard Medical School. My studies focus on the mechanisms regulating immune tolerance in autoimmune liver diseases. The ultimate goal of my research is to devise new forms of immunotherapy for the treatment of these conditions.

Liver scientist with a strong research interest on uncovering the fundamental mechanisms driving the onset and progression of chronic liver disease, with particular interest in hepatic DAMPs, immune cell activation, and immune suppression across early and advanced disease stages.

I am a physician scientist and pediatric transplant hepatologist at Northwestern Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago. My research focuses on basic and translational studies investigating the unfolded protein response (UPR) in murine models of cholestatic liver disease and pediatric cholestatic liver diseases.